SiNtx Technologies – Consensus Indicates Potential 142.0% Upside

Broker Ratings

SiNtx Technologies with ticker code (SINT) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 4.5 and 4.25 with the average target price sitting at 4.38. With the stocks previous close at 1.81 this now indicates there is a potential upside of 142.0%. The 50 day moving average now sits at 2.22 while the 200 day moving average is 1.9. The company has a market cap of $71m. You can visit the company’s website by visiting: http://www.sintx.com

Sintx Technologies, a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. It offers ceramic based biomaterial solutions in various medical and industrial applications. The company provides spine implant products under the Valeo brand to surgeons and hospitals for use in cervical and thoracolumbar spine surgery. Sintx Technologies markets and sells its products directly; and through direct sales organizations, distributors, as well as original equipment manufacturer and private label partnerships. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies in October 2018. Sintx Technologies was founded in 1996 and is headquartered in Salt Lake City, Utah.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index